OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
OKYO Pharma LTD has commenced the trial process for its treatment of dry eye disease.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Limited (AIM:OKYO) Custom Clearance of GMP Packaged OK-101 Drug
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) Appointment to Scientific Advisory Board
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 20 to Number 1
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 5 to 1
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 10 to 6
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
OKYO Pharma LTD (AIM:OKYO) Interim Results for the Six Months Ending 30 September 2022
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 15 to 11
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 20 to 16
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are